Pancreatic function assessment in type 1 diabetes mellitus patients according to disease duration;Avaliação da função pancreática em pacientes com diabetes melito tipo 1 de acordo com a duração da doença

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 53, Issue 1, 2009, Pages 64-71

  Dantas, Joana R ^a,b   Almeida, Mirella H ^b   Barone, Bianca ^a,b   Campos, Felipe ^b   Kupfer, Rosane ^a   Milech, Adolpho ^b   Zajdenverg, Lenita ^b   Rodacki, Melanie ^a,b   de Oliveira, José Egídio P ^b  

^a Endocrinologia Luiz Capriglione (IEDE)   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

C peptide; Disease duration; Insulin secretion; Type 1 diabetes

Indexed keywords

C PEPTIDE; DIAGNOSTIC AGENT; GLUCAGON; GLUTAMATE DECARBOXYLASE; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADOLESCENT; ADULT; ARTICLE; CHI SQUARE DISTRIBUTION; ETHNOLOGY; FEMALE; HUMAN; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLISM; PANCREAS; PATHOPHYSIOLOGY; SECRETION; TIME;

ADOLESCENT; C-PEPTIDE; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCAGON; GLUTAMATE DECARBOXYLASE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE; PANCREAS; TIME FACTORS; YOUNG ADULT;

EID: 66149104539     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001;358:221-9
2. Daneman D. Type 1 Diabetes. Lancet. 2006;367:847-58.
3. Screenan S, Pick AJ, Levisettim, Baldwin AC, Pugh W, Polonsky KS. Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes. 1999;48: 989-96.
4. Marchetti P, Dotta F, Zhiong L, Lupi R, Del Guerra S, Santangelo C, et al. The function of pancreatic islets isolated from type 1 diabetic patient. Diabetes Care. 2000;23:701-3.
5. Tsai EB, Sherry NA, Palmer JP, Herold KC, for the DPT-1 Study Group. The Rise and Fall of Insulin Secretion in type 1 diabetes mellitus. Diabetologia. 2006;49:261-70.
6. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, et al. C-peptide is the appropriate outcome measure for type1 diabetes clinical trials to preserve beta cell function - ADA Workshop Report. Diabetes. 2004;53:250-64.
7. Vendrame F, Zappaterreno A, Dotta F. Markers of beta cell function in type 1 diabetes mellitus. Minerva Med. 2004;95:1-6.
8. Steffes MW, Sibley S, Jackson M, Thomas W. β-cell Function and the development of diabetes-related complications in diabetes control and complication trial. Diabetes Care. 2003;26:832-6.
9. Sherry NA, Tsai EB, Palmer JP, Herold KC. Natural history of beta cell function in type 1 diabetes. Diabetes. 2005;54:Suppl 2:S32-9.
10. The Diabetes Control and Complications Trial Research Group: the effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. Ann Intern Med. 1998;128:517-53.
11. Eisenbarth GS. Type 1 diabetes mellitus. In: Kahn CR, Weir GC, King GL, Moses AC, Smith RJ, Jacobson AM, editors. Joslin's diabetes mellitus. 14. ed. Boston, MA: Lippincott Williams & Wilkins; 2005. p. 399-424.
12. American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus (position statements). Diabetes Care. 2005;28 Suppl 1:S37-42.
13. Rodacki M, Zajdenverg L, Tortora RP, Reis FA, Albernaz MS, Goncalves MR, et al. Characteristics of childhood and adult-onset type 1 diabetes in a multi-ethnic population. Diab Res Clin Pract. 2005;69:22-8.
14. Palatnik M, Silva Junior WA, Estalote AC, Oliveira JEP, Milech A, Zago MA. Ethnicity and type 2 diabetes in Rio de Janeiro, Brazil, with a review of the prevalence of the disease in Amerindians. Hum Biol. 2002;74:533-44.
15. Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, et al. Insulin secretion in type 1 diabetes. Diabetes. 2004;53:426-33.
16. Pozzan R, Dimetz T, Gazzola HM, Gomes MB. The C-peptide response to a standard mixed meal in a group of Brasilian type 1 diabetic patients. Braz J Med Biol Res. 1997;30(10):1169-74.
17. Keenan HA, Berger A, Sun JK, Eisenbath G, Doria A, King GL. Demonstration of islet cell function in patients with 50 years or longer of diabetes. Diabetes. 2007;56 Supl 1:A386.
18. Snorgaard O, Larsen LH, Binder C. Homogeneity in patter of decline of β-cell function in IDDM. Diabetes Care 15:1009-1015, 1992.
19. Rodacki M, Dantas J, Nabuco A, Barone B, et al. Diabetic ketoacidosis at the onset of type 1 diabetes:frequency and interfering factors. American Diabetes Association 67th Annnual Scentific Sessions. 2007;0918-P.
20. Karjalainen J, Salmela P, Ilonen J, Surcel HM, Knip M. A comparison of childhood and adult type 1 diabetes. N Engl J Med. 1989;320:881-6.
21. Leslie RDG, Williams R, Pozzilli P. Clinical Review: type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab. 2006;91:1654-9.
22. Madsbad S, Krarup T, Regeur L, Faber OK, Binder C. Effect of strict blood glucose control on residual B-cell function in insulin-dependent diabetics. Diabetologia. 1981;20:530-4.
23. Rodacki M, Zajdenverg L, Albernaz MS, Bencke-Gonçalves MR, Milech A, Oliveira JE. Relationship between the prevalence of anti-glutamic acid descarboxilase autoantibodies and duration of type 1 diabetes mellitus in Brazilian patients. Braz J Med Biol Res. 2004;37(11):1645-50.
24. Dantas J, Almeida MH, Barone B, Suzundy R, Rodacki M, Zajdenverg L, et al. Fatores clínico e epidemiológicos associados a positividade do anti-GAD em pacientes com diabetes mellitus tipo 1 (DM1) e longa duração de doença. Arq Bras Endocrinol Metab. 2007;51 Supl1:S485.
25. Pardini VC, Mourao DM, Nascimento PD, Vivolo MA, Ferreira SR, Pardini H. Frequency of islet cell autoantibodies (IA-2 and GAD) in young Brazilian type 1 diabetes patients. Braz J Med Biol Res. 1999;32:1195-8.
26. Wallensten M, Dahlquist G, Persson B, Landin-Olsson M, Lernmark Å, Sundkvist G. Thalme B. Factors influencing the magnitude, duration, and rate of fall of b-cell function in type 1 (insulin dependent) diabetic children followed for two years from their clinical diagnosis. Diabetologia. 1988; 31:664-9.
27. Decochez K, Keymeulen B, Somers G. Use of an islet cell antibody assay to identify type 1 diabetic patients with rapid decrease in C-peptide levels after clinical onset: Belgium Diabetes Registry. Diabetes Care. 1996;19:1357-63.
28. Törn C, Olsson L, Lernmark A, Palmer JP, Arnqvist HJ, Blohmé G, et al. Prognostic fators for the course of β cell function in autoimmune diabetes. J Clin Endocrinol Metab. 2000;85:4619-23.